EC Number   |
Natural Substrates |
|---|
    1.13.11.34 | more |
inhibition of COX pathways does not increase the transformation of arachidonic acid by the 5-LOX pathway |
| 1.13.11.34 | more |
key enzyme in biosynthesis of leukotrienes, overview. Upon cell activation, cytosolic and nuclear enzyme translocates the nuclear envelope, where it interacts with phospholipase A2, making free arachidonate available for 5-LO, and with 5-LO activating protein, i.e. FLAP. 5-LO regulates cancer cell survival and interferes with the mechanismtumor suppression, and increases cancer cell chemoresistance, overview |
| 1.13.11.34 | more |
key enzyme in the leukotriene biosynthesis, pathway overview, regulatory mechanisms underlying the expression and control of 5-LO activity, overview |
| 1.13.11.34 | more |
key enzyme in the leukotriene biosynthesis, pathway overview, the 5-LO pathway is linked to the development of cardiovascular disease and other diseases, regulatory mechanisms underlying the expression and control of 5-LO activity, overview |
| 1.13.11.34 | more |
no significant effect of LTB4, 12-hydroperoxyeicosatetraenoic acid or 15-hydroperoxyeicosatetraenoic acid on leukemic blast growth and on their apoptose rate, overview |
| 1.13.11.34 | more |
the enzyme is involved in survival of Epstein-Barr virus-converted B lymphoma cells via function of 5-hydroperoxyeicosatetraenoic acid, overview |
| 1.13.11.34 | more |
the enzyme is the key enzyme in biosynthesis of biologically active leukotrienes |
| 1.13.11.34 | more |
the enzyme, catalyzing the key step in leukotriene biosynthesis, interacts with methyl jasmonate, which is probably involved in the anticarcinogenic activity of methyl jasmonate inducing apoptosis, overview |
| 1.13.11.34 | more |
the enzyme catalyzes the dioxygenation of polyunsaturated fatty acids |
